Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Single Arm Phase IV Study of Afatinib in Elderly Patients With Stage IV or Recurrent Non-Small Cell Lung Cancer Whose Tumors Have Epidermal Growth Factor Receptor (EGFR) Exon 19 Deletions or Exon 21(L858R) Substitution Mutations

NCT02514174 is registered in ClinicalTrials.gov with Boehringer Ingelheim as lead sponsor.

NCT NCT02514174
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02514174 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Single Arm Phase IV Study of Afatinib in Elderly Patients With Stage IV or Recurrent Non-Small Cell Lung Cancer Whose Tumors Have Epidermal Growth Factor Receptor (EGFR) Exon 19 Deletions or Exon 21(L858R) Substitution Mutations
Lead sponsor
Boehringer Ingelheim
Phase
Phase 4
Overall status
Completed
Start date
August 18, 2015
Completion date
April 25, 2019
Enrollment
25 (actual)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

carcinoma, non-small-cell lung, erbb receptors